France's Inventiva prelim 2025 revenue misses analyst expectations

Inventiva SA

17/02/2026 07:39

Overview

France-based biopharma's prelim 2025 revenue of €4.5 mln missed analyst expectations

Company completed U.S. public offering, raising approximately $172.5 mln

R&D expenses fell 4% to €86.9 mln, mainly for lanifibranor development

Outlook

Company expects cash runway until mid-Q1 2027

Company sees potential funding extension to mid-Q3 2027 with Tranche 3 warrants

Result Drivers

REVENUE DECLINE - Co's revenue fell to €4.5 mln in 2025, down from €9.2 mln in 2024, mainly due to lower revenues under the licensing agreement with CTTQ

CASH POSITION - Completed U.S. public offering raised approximately $172.5 mln, boosting cash reserves

COST MANAGEMENT - R&D expenses decreased by 4% to €86.9 mln, mainly related to lanifibranor development

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Miss
EUR 4.5 mln
EUR 7.27 mln (7 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Inventiva SA is €11.40, about 115.9% above its February 16 closing price of €5.28

Press Release: ID:nGNE7sgj60

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)